Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts
The functional receptor to SARS-CoV-2, the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic, is angiotensin-converting enzyme-2 (ACE-2), the same enzyme that physiologically counters the renin-angiotensin system (RAS) activation. Some researchers have questioned RAS inhibitors’...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | International Journal of Hypertension |
| Online Access: | http://dx.doi.org/10.1155/2020/1025913 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561176591990784 |
|---|---|
| author | Kunal Mahajan Prakash Chand Negi Neeraj Ganju Sachin Sondhi Naresh Gaur Rao Somendra |
| author_facet | Kunal Mahajan Prakash Chand Negi Neeraj Ganju Sachin Sondhi Naresh Gaur Rao Somendra |
| author_sort | Kunal Mahajan |
| collection | DOAJ |
| description | The functional receptor to SARS-CoV-2, the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic, is angiotensin-converting enzyme-2 (ACE-2), the same enzyme that physiologically counters the renin-angiotensin system (RAS) activation. Some researchers have questioned RAS inhibitors’ safety in COVID-19 patients since these drugs have demonstrated an increase in ACE-2 expression in preclinical studies; therefore, they may facilitate viral invasion. On the contrary, others have hypothesized a protective role of RAS inhibitors against COVID-19-associated lung injury. Overall, the data are grossly inadequate to reach any conclusion since no human trials have yet evaluated the effects of RAS inhibitors in COVID-19. We review the current data and pathophysiological mechanisms behind this intriguing interplay between the RAS inhibitors and the COVID-19. |
| format | Article |
| id | doaj-art-c735ecb3cb91486780950588f481dfd1 |
| institution | Kabale University |
| issn | 2090-0384 2090-0392 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hypertension |
| spelling | doaj-art-c735ecb3cb91486780950588f481dfd12025-02-03T01:25:45ZengWileyInternational Journal of Hypertension2090-03842090-03922020-01-01202010.1155/2020/10259131025913Renin-Angiotensin System Inhibitors in COVID-19: Current ConceptsKunal Mahajan0Prakash Chand Negi1Neeraj Ganju2Sachin Sondhi3Naresh Gaur4Rao Somendra5Department of Cardiology, Indira Gandhi Medical College, Shimla 171001, IndiaDepartment of Cardiology, Indira Gandhi Medical College, Shimla 171001, IndiaDepartment of Cardiology, Indira Gandhi Medical College, Shimla 171001, IndiaACE Heart and Vascular Institute, Mohali, Punjab 160062, IndiaDepartment of Cardiology, Indira Gandhi Medical College, Shimla 171001, IndiaDepartment of Cardiology, Indira Gandhi Medical College, Shimla 171001, IndiaThe functional receptor to SARS-CoV-2, the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic, is angiotensin-converting enzyme-2 (ACE-2), the same enzyme that physiologically counters the renin-angiotensin system (RAS) activation. Some researchers have questioned RAS inhibitors’ safety in COVID-19 patients since these drugs have demonstrated an increase in ACE-2 expression in preclinical studies; therefore, they may facilitate viral invasion. On the contrary, others have hypothesized a protective role of RAS inhibitors against COVID-19-associated lung injury. Overall, the data are grossly inadequate to reach any conclusion since no human trials have yet evaluated the effects of RAS inhibitors in COVID-19. We review the current data and pathophysiological mechanisms behind this intriguing interplay between the RAS inhibitors and the COVID-19.http://dx.doi.org/10.1155/2020/1025913 |
| spellingShingle | Kunal Mahajan Prakash Chand Negi Neeraj Ganju Sachin Sondhi Naresh Gaur Rao Somendra Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts International Journal of Hypertension |
| title | Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts |
| title_full | Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts |
| title_fullStr | Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts |
| title_full_unstemmed | Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts |
| title_short | Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts |
| title_sort | renin angiotensin system inhibitors in covid 19 current concepts |
| url | http://dx.doi.org/10.1155/2020/1025913 |
| work_keys_str_mv | AT kunalmahajan reninangiotensinsysteminhibitorsincovid19currentconcepts AT prakashchandnegi reninangiotensinsysteminhibitorsincovid19currentconcepts AT neerajganju reninangiotensinsysteminhibitorsincovid19currentconcepts AT sachinsondhi reninangiotensinsysteminhibitorsincovid19currentconcepts AT nareshgaur reninangiotensinsysteminhibitorsincovid19currentconcepts AT raosomendra reninangiotensinsysteminhibitorsincovid19currentconcepts |